Central Nervous System Complications Among Oncology Patients

Hematol Oncol Clin North Am. 2022 Feb;36(1):217-236. doi: 10.1016/j.hoc.2021.08.005. Epub 2021 Oct 2.

Abstract

Cancer treatment related injury to the central nervous system (CNS) is well-recognized in the setting of brain-directed radiation therapies and conventional and novel systemic anticancer therapies. Late-delayed treatment-induced CNS complications frequently result in permanent neurologic disability. Therapeutic options are supportive with limited clinical benefit, whereby alteration or discontinuation of the overall antineoplastic treatment plan is frequently necessary to prevent further neurologic injury. Better identification of patients at high risk for developing late CNS toxicities, neuroprotective strategies with modification of existing antineoplastic treatment regimens, and research efforts directed at earlier recognition and improved treatment of central neurologic complications are paramount.

Keywords: Chemotherapy; Immunotherapy; Neurologic complications; Radiation therapy; Targeted therapy.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / adverse effects
  • Central Nervous System
  • Central Nervous System Diseases*
  • Humans
  • Immunotherapy
  • Medical Oncology
  • Neoplasms* / complications
  • Neoplasms* / drug therapy

Substances

  • Antineoplastic Agents